Long-term data do not support Raltegravir as second-line HIV therapy
826  

Long-term data do not support Raltegravir as second-line HIV therapy

A second-line HIV regimen containing the integrase inhibitor raltegravir failed to meet its primary endpoint of noninferiority against standard second-line treatment with nucleoside reverse-transcriptase inhibitors, or NRTIs, according to 144-week data from the EARNEST trial.

November 20, 2017
News